Raising the Flag for Mast Cells as a Novel Target in Lymphangioleiomyomatosis.
作者信息
Goldklang Monica
机构信息
Columbia University Irving Medical Center New York, New York.
出版信息
Am J Respir Crit Care Med. 2021 Aug 15;204(4):387-389. doi: 10.1164/rccm.202104-0872ED.
Abstract
摘要
相似文献
1
Raising the Flag for Mast Cells as a Novel Target in Lymphangioleiomyomatosis.
Am J Respir Crit Care Med. 2021 Aug 15;204(4):387-389. doi: 10.1164/rccm.202104-0872ED.
2
Chronic sirolimus therapy for lymphangioleiomyomatosis.
Am J Respir Crit Care Med. 2014 Dec 15;190(12):1332-3. doi: 10.1164/rccm.201411-2032ED.
3
Durability of Sirolimus for Lymphangioleiomyomatosis.
Am J Med Sci. 2017 Dec;354(6):603-607. doi: 10.1016/j.amjms.2016.11.028. Epub 2016 Dec 5.
4
Lymphangioleiomyomatosis treatment with sirolimus.
Arch Bronconeumol. 2011 Sep;47(9):470-2. doi: 10.1016/j.arbres.2011.01.014. Epub 2011 Mar 25.
5
Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation?
Expert Rev Respir Med. 2014 Dec;8(6):657-60. doi: 10.1586/17476348.2014.956728. Epub 2014 Sep 9.
6
Lymphangioleiomyomatosis.
Eur J Intern Med. 2009 Jan;20(1):e24. doi: 10.1016/j.ejim.2008.07.020. Epub 2008 Aug 24.
7
[Consensus Statement: sirolimus (rapamycin) as therapy for lymphangioleiomyomatosis (2018)].
Zhonghua Jie He He Hu Xi Za Zhi. 2019 Feb 12;42(2):92-97. doi: 10.3760/cma.j.issn.1001-0939.2019.02.002.
8
Sirolimus for lymphangioleiomyomatosis lesions.
N Engl J Med. 2008 May 1;358(18):1963-4; author reply 1964. doi: 10.1056/NEJMc086040.
9
Lymphangioleiomyomatosis: unsuccessful treatment with luteinizing-hormone-releasing hormone analogues.
Eur J Med. 1993 Jun-Jul;2(6):377-8.
10
[Lymphangioleiomyomatosis a rare disease in a young women].
Duodecim. 1997;113(2):149-52.
本文引用的文献
1
Mast-Cell Tryptase Release Contributes to Disease Progression in Lymphangioleiomyomatosis.
Am J Respir Crit Care Med. 2021 Aug 15;204(4):431-444. doi: 10.1164/rccm.202007-2854OC.
2
Long-term efficacy and safety of sirolimus therapy in patients with lymphangioleiomyomatosis.
Orphanet J Rare Dis. 2019 Aug 20;14(1):206. doi: 10.1186/s13023-019-1178-2.
3
Rapalog resistance is associated with mesenchymal-type changes in Tsc2-null cells.
Sci Rep. 2019 Feb 28;9(1):3015. doi: 10.1038/s41598-019-39418-5.
4
Dysregulation of the endothelin pathway in lymphangioleiomyomatosis with no direct effect on cell proliferation and migration.
Sci Rep. 2018 Oct 2;8(1):14698. doi: 10.1038/s41598-018-32795-3.
5
Immunohistological features related to functional impairment in lymphangioleiomyomatosis.
Respir Res. 2018 May 8;19(1):83. doi: 10.1186/s12931-018-0797-9.
6
Effect of beta-agonists on LAM progression and treatment.
Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):E944-E953. doi: 10.1073/pnas.1719960115. Epub 2018 Jan 16.
7
Efficacy and Safety of Long-Term Sirolimus Therapy for Asian Patients with Lymphangioleiomyomatosis.
Ann Am Thorac Soc. 2016 Nov;13(11):1912-1922. doi: 10.1513/AnnalsATS.201605-335OC.
8
Mesenchymal Tumorigenesis Driven by TSC2 Haploinsufficiency Requires HMGA2 and Is Independent of mTOR Pathway Activation.
Cancer Res. 2016 Feb 15;76(4):844-54. doi: 10.1158/0008-5472.CAN-15-1287. Epub 2016 Feb 2.
9
Surfactant dysfunction and lung inflammation in the female mouse model of lymphangioleiomyomatosis.
Am J Respir Cell Mol Biol. 2015 Jul;53(1):96-104. doi: 10.1165/rcmb.2014-0224OC.
10
Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis.
Am J Respir Crit Care Med. 2014 Dec 1;190(11):1273-82. doi: 10.1164/rccm.201405-0918OC.
Zotero 插件